Emergent BioSolutions Inc.
EBSNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $742.9M | $1.04B | $1.05B | $1.12B | $1.77B | $192.5M |
| Operating income | $100.1M | −$108.7M | −$726.4M | −$170.0M | $341.4M | $433.8M |
| Net income | $52.6M | −$190.6M | −$760.5M | −$211.6M | $219.5M | $305.1M |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B | $2.88B |
| Total liabilities | $796.0M | $906.9M | $1.17B | $1.78B | $1.34B | $1.44B |
| Equity | $522.6M | $482.8M | $649.3M | $1.39B | $1.61B | $1.45B |
| EPS (diluted) | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 | $5.67 |
| Shares out. | 54.3M | 52.2M | 50.1M | 50.5M | 53.3M | 52.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 13.5%
- Net margin
- 7.1%
- Return on equity
- 10.1%
- Return on assets
- 4.0%
- Return on capital (ROCE)
- 8.4%
- Liabilities / assets
- 60.4%
- Debt / equity
- 1.52×
- Book value / share
- $9.62
- Revenue growth (YoY)
- −28.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.44safe
- Accruals / assets
- −8.9%clean
- Beneish M-Score
- -3.57normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Operating margin is positive
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 9, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 4Enrolling By Invitationreadout ~2028-07-31BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
- Phase 4Not Yet Recruitingreadout ~2035-05Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Dimensional Fund Advisors LpPassive (13G)Apr 9, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- State Street CorpPassive (13G)Feb 9, 2026
- Blackrock, Inc.Passive (13G)Jul 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Dayal Sujata TyagiDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Degolyer Donald WDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Katkin KeithDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| White Marvin LDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Fowler John D JrDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Richard RonaldDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Zoon Kathryn CDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Fowler Neal FranklinDirector | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Harsanyi ZsoltOfficer — Chairman | Apr 30, 2026 | Grant | 25,344 | $0.00 |
| Williams Paul AnthonyOfficer — SVP, Products Business | Apr 29, 2026 | Grant | 100,111 | $0.00 |
| Lowry Simon COfficer — SVP, R&D, CMO | Apr 29, 2026 | Grant | 100,111 | $0.00 |
| Glessner ColeenOfficer — EVP, Quality & Ethics, and CPL | Apr 29, 2026 | Grant | 100,111 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.6M | 12.0 | -1.8% |
| Apr 30, 2026 | 9.8M | 18.4 | +1.4% |
| Apr 15, 2026 | 9.6M | 13.5 | -0.1% |
| Mar 31, 2026 | 9.7M | 11.3 | +8.7% |
| Mar 13, 2026 | 8.9M | 7.4 | -1.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureApr 30, 2026
- Shareholder voteApr 30, 2026
- Entered a material agreement · Terminated a material agreement · Unregistered equity sale · Regulation FD disclosureApr 17, 2026
- Director / officer change · Regulation FD disclosureMar 3, 2026
- Results of operations · Regulation FD disclosureFeb 26, 2026
- Regulation FD disclosureJan 14, 2026
- Regulation FD disclosureJan 12, 2026
- Regulation FD disclosureDec 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spin-offs from Emergent BioSolutions Inc. (1)
- Aptevo Therapeutics Inc.APVOcompletedAug 1, 2016details
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.